Related Experiment Video

Updated: Jul 4, 2025

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
02:47

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

1.4K

Clinical Translation of Cardiovascular Biomarkers - A Long and Uncertain Road

Jonathan W Cunningham1, Marc A Pfeffer1

  • 1Cardiovascular Division, Brigham and Women's Hospital, Boston.

NEJM Evidence
|February 6, 2024
PubMed

Insights

Novel cardiovascular biomarkers are crucial for research, risk assessment, and targeted therapies. Evaluating their clinical utility requires assessing reproducibility, added information value, and impact on patient care.

Area of Science:

  • Cardiovascular Medicine
  • Biomarker Discovery
  • Clinical Diagnostics

Background:

  • Cardiovascular biomarkers are vital for understanding disease mechanisms and guiding patient treatment.
  • A 2007 framework proposed by Morrow and de Lemos outlines criteria for evaluating new cardiovascular biomarkers.
  • These criteria focus on reproducibility, incremental information, and clinical utility in patient care.

Discussion:

  • The clinical utility of a biomarker is paramount in distinguishing research tools from clinical instruments.
  • Reproducibility in clinical laboratory settings is a fundamental requirement for biomarker adoption.
  • Assessing whether a biomarker provides new information beyond existing diagnostic tests is critical.

Key Insights:

  • Novel biomarkers must demonstrate consistent and reliable measurement.
  • The added value of a biomarker over current tests determines its clinical significance.
  • The ultimate test for a biomarker is its ability to improve patient management and outcomes.

Outlook:

  • Future research should focus on biomarkers that directly enhance clinical decision-making.
  • Development of robust assays is essential for the widespread clinical application of cardiovascular biomarkers.
  • Translating research biomarkers into clinically actionable tools remains a key challenge in cardiovascular medicine.

More Related Videos

Using Extraordinary Optical Transmission to Quantify Cardiac Biomarkers in Human Serum09:23

Using Extraordinary Optical Transmission to Quantify Cardiac Biomarkers in Human Serum

Published on: December 13, 2017

6.3K
In Silico Clinical Trials for Cardiovascular Disease09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

1.7K

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
92
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
158